Several clinical manifestations and laboratory findings have been found to be associated to increased risk of mortality in univariable analyses (1). Objectives: Here we present a mortality predicting model in a long-term observational unselected nationwide cohort aiming to enhance the knowledge of long-term prognosis in MCTD. Methods: 135 patients were included from our nationwide MCTD cohort. Abnormal high resolution computed tomography (CT) findings of ground glass attenuation and reticular patterns were defined as Interstitial Lung Disease (ILD) and expressed as percentage of Total Lung Volume (TLV). Pulmonary function tests and laboratory tests were performed within 2 months of the HRCT examination. Pleuritis was defined as typical pleurisity for more than one day, pleural effusions or pleural rub present at or before baseline. Pericarditis was defined as typical pericardial pain for more than one day, pericardial effusion, pericardial rub or pericarditis by electrocardiography at or before baseline. Myositis was confirmed by muscle biopsy and/or electromyogram and CK elevation at or before baseline. Cox regression analyses were used to find the predictive factors of mortality. Variables at a significant level of P<.25 where considered a candidate in the prediction model by manual backward elimination procedure. Results: 21 patients died after a mean (standard deviation) observation of 9 (2) years. The predictive model is shown in Table 1 . According to the Harrell's C index, patient outcomes were accurately predicted by this model 85% of the time. . FVC = Forced Vital Capacity % of predicted, DLCO = diffusing capacity of the lung for carbon monoxide % of predicted, ESR = erythrocyte sedimentation rate, TLV = total lung volume, Hb = Haemoglobin.
Conclusions:
The strongest predicting factors of mortality in MCTD is increasing % ILD of TLV, pericarditis, male gender, DLCO less than 60% of predicted and increasing age at diagnosis. Background: Immune checkpoint inhibitors (specifically the anti-CTLA-4 antibody ipilimumab, and the anti-PD-1 antibodies nivolumab and pembrolizumab, have revolutionized the treatment of advanced malignancies. However, by virtue of their mechanism of action -that is, loss of T-cell inhibition and impaired self-tolerance, patients with underlying autoimmune and rheumatologic diseases were typically excluded from the clinical trials leading to the approval of these agents. Limited data, typically of single checkpoint inhibitors, exist for their safety in patients with autoimmune diseases. However, the risk for rheumatologic disease flare in patients exposed to checkpoint inhibitors is unknown. Objectives: To determine the risk of rheumatologic disease flare in patients receiving checkpoint inhibitor therapy.
Methods:
We retrospectively studied all patients who had received a checkpoint inhibitor (i.e. ipilimumab, nivolumab, pembrolizumab, or 
